Best response to treatment by carfilzomib dose, ISS stage, and cytogenetics (N = 53)
| . | Response, n (%)* . | |||
|---|---|---|---|---|
| ≥ PR . | ≥ VGPR . | ≥ nCR . | sCR . | |
| Carfilzomib dose, mg/m2 | ||||
| 20 (n = 4) | 4 (100) | 4 (100) | 3 (75) | 1 (25) |
| 27 (n = 13) | 13 (100) | 13 (100) | 10 (77) | 7 (54) |
| 36 (n = 36) | 35 (97) | 26 (72) | 20 (55) | 14 (39) |
| ISS stage | ||||
| I (n = 21) | 21 (100) | 16 (76) | 12 (57) | 7 (33) |
| II (n = 18) | 18 (100) | 15 (75) | 10 (55) | 8 (44) |
| III (n = 14) | 13 (93) | 12 (86) | 11 (79) | 7 (50) |
| Cytogenetics | ||||
| Normal/favorable (n = 34)† | 34 (100) | 26 (76) | 20 (59) | 13 (38) |
| Unfavorable (n = 17)† | 16 (94) | 13 (76) | 11 (65) | 9 (53) |
| . | Response, n (%)* . | |||
|---|---|---|---|---|
| ≥ PR . | ≥ VGPR . | ≥ nCR . | sCR . | |
| Carfilzomib dose, mg/m2 | ||||
| 20 (n = 4) | 4 (100) | 4 (100) | 3 (75) | 1 (25) |
| 27 (n = 13) | 13 (100) | 13 (100) | 10 (77) | 7 (54) |
| 36 (n = 36) | 35 (97) | 26 (72) | 20 (55) | 14 (39) |
| ISS stage | ||||
| I (n = 21) | 21 (100) | 16 (76) | 12 (57) | 7 (33) |
| II (n = 18) | 18 (100) | 15 (75) | 10 (55) | 8 (44) |
| III (n = 14) | 13 (93) | 12 (86) | 11 (79) | 7 (50) |
| Cytogenetics | ||||
| Normal/favorable (n = 34)† | 34 (100) | 26 (76) | 20 (59) | 13 (38) |
| Unfavorable (n = 17)† | 16 (94) | 13 (76) | 11 (65) | 9 (53) |
ISS indicates International Staging System; nCR, near-complete response; PR, partial response; and VGPR, very good partial response.
Assessed by Modified IMWG Uniform Criteria with the addition of nCR.
Any of del 13 by metaphase or hypodiploidy or t(4;14) or t(14;16) or del 17p considered as unfavorable; all others considered normal/favorable.